Get the Stockscreener App
459.21
0.24%
-1.10
Vertex Pharmaceuticals Inc stock is traded at $459.21, with a volume of 767.93K.
It is down -0.24% in the last 24 hours and up +7.60% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$460.31
Open:
$460.44
24h Volume:
767.93K
Relative Volume:
0.52
Market Cap:
$116.51B
Revenue:
$11.74B
Net Income/Loss:
$3.68B
P/E Ratio:
32.36
EPS:
14.1888
Net Cash Flow:
$3.34B
1W Performance:
+0.93%
1M Performance:
+7.60%
6M Performance:
+3.53%
1Y Performance:
+13.31%
1-Day Range:
$457.04
$461.49
1-Week Range:
$445.41
$461.49
52-Week Range:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
459.21 | 116.79B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.17 | 81.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.70 | 53.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
845.95 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.77 | 37.48B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by DAVENPORT & Co LLC - MarketBeat
Andrew Hill Investment Advisors Inc. Sells 4,294 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Anderson Hoagland & Co. - MarketBeat
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress - Yahoo Finance UK
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12 - Business Wire
Vertex Pharmaceuticals: Strong Journavx Launch and Durable CF Franchise Underpin Buy Rating and Long-Term Growth Upside - TipRanks
Best Biotech Stocks To Watch TodayDecember 21st - MarketBeat
Best Biotech Stocks To Watch NowDecember 16th - MarketBeat
Foster Victor Wealth Advisors LLC Has $13.66 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Flputnam Investment Management Co. Sells 3,065 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Congress Asset Management Co. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch - ts2.tech
Redhawk Wealth Advisors Inc. Lowers Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
LVM Capital Management Ltd. MI Trims Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open - ts2.tech
Is Vertex Pharmaceuticals Incorporated stock ready for breakoutJuly 2025 Selloffs & Daily Entry Point Trade Alerts - Улправда
Aug Analyst Calls: Is Vertex Pharmaceuticals Incorporated stock ready for breakout2025 Price Targets & Weekly Sector Rotation Insights - ulpravda.ru
What dividend safety score for Vertex Pharmaceuticals Incorporated stockWeekly Investment Report & Weekly High Return Forecasts - Улправда
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Voya Investment Management LLC Has $168.85 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Montecito Bank & Trust Buys Shares of 2,239 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated stock attractive after correctionQuarterly Trade Summary & Daily Stock Trend Reports - Bölüm Sonu Canavarı
Is Vertex Pharmaceuticals Incorporated stock positioned well for digital economy2025 Technical Patterns & Weekly Breakout Watchlists - Улправда
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Ipswich Investment Management Co. Inc. - MarketBeat
Thurston Springer Miller Herd & Titak Inc. Sells 2,487 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Czech National Bank Increases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
How analysts rate Vertex Pharmaceuticals Incorporated stock todayEarnings Miss & Reliable Intraday Trade Plans - Улправда
Vertex Pharmaceuticals Incorporated $VRTX Stake Lessened by Channel Wealth LLC - MarketBeat
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gradient Investments LLC Boosts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Corient Private Wealth LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Assenagon Asset Management S.A. Increases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
2 Reasons to Watch VRTX and 1 to Stay Cautious - The Globe and Mail
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Vertex, Inc. (VERX) Stock News Today: Latest Price, AI Tax Automation Updates, Analyst Forecasts and Outlook (Dec. 16, 2025) - ts2.tech
Texas Permanent School Fund Corp Sells 9,892 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Shorepoint Capital Partners LLC Invests $4.08 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
12 Days of Investing: My Top 12 Stocks to Buy Before 2026 - The Motley Fool
What's Driving the Market Sentiment Around Vertex Pharmaceuticals Inc?Vertex Pharmaceuticals (NASDAQ:VRTX) - Benzinga
National Bank of Canada FI Acquires 99,751 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Castleark Management LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
B. Riley Wealth Advisors Inc. Buys Shares of 4,141 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025 - ts2.tech
MASTERINVEST Kapitalanlage GmbH Purchases Shares of 5,784 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Westwood Holdings Group Inc. - MarketBeat
Lazard Asset Management LLC Has $213.83 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Provident Investment Management Inc. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Position Lifted by Liontrust Investment Partners LLP - MarketBeat
Marex Group plc Invests $2.98 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
2.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):